Novacyt Picks Up Bargain With Omega's Infectious Disease Unit
Executive Summary
Clinical diagnostics firm Novacyt's M&A growth strategy is underway with the company announcing a bargain deal to buy the infectious disease business of Omega Diagnostics.
You may also be interested in...
Novacyt Lands New US Supply Deal, Maps Path To Profitability
Novacyt is continuing its quest to reach profitability in 2018. The French diagnostics group has entered into a partnership with US lab Genesis Diagnostics to develop and supply molecular assay panels for a range of indications. The five-year deal is worth a minimum of $3m, but Novacyt said it expects the agreement to deliver more significant returns.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.